How has the ASCENT trial impacted your management of previously treated metastatic TNBC?

The phase III ASCENT trial demonstrated improved progression-free survival and overall survival with sacituzumab govitecan over single-agent chemotherapy of physician’s choice (TPC) in metastatic triple-negative breast cancer (mTNBC). All the sub-groups derived benefit, including <65 vs >=65, initia...

Using sacituzumab 2nd line when possible, definitely third line.

The approval of sacituzumab has given us a powerful tool in our bag of options for TNBC. In the ASCENT trial, remember that treatment of physician’s choice (TPC) chemotherapy performed very poor with a mPFS in the TPC arm of less than 2 months. Having a drug that not only improves PFS (1.7 to 4. 8 m...